Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>
"INO has extraordinary potential; I really want to see CEO Joseph Kim and Dave Weiner push this technology into the future." (10/24/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Patrick Cox Moreá>
"CPRX is an emerging biotechnology company in the white hot space of orphan drug medicines." (11/7/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Scott Henry Moreá>
"BDSI's buprenorphine product for chronic pain could be a $500M+/year revenue-generating drug if approved." (11/7/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Scott Henry Moreá>
Grant Zeng has more than 10 years' professional experience in equity research and analysis. He is currently a senior biotech analyst with Zacks Investment Research Inc., and has been with Zacks since March 2006. Before joining Zacks, Zeng worked for TheStreet.com as a biotech analyst from 2005-2006. From September 2001 to December 2003, Zeng worked for China Pacific Insurance Co. as an equity/fund analyst. Zeng was a healthcare equity analyst with Young & Partners LLC from August 2000 to September 2001. Zeng also has teaching and research experience in pharmaceutical science. Zeng obtained his master's of business administration with a major in finance in 2000 from McMaster University, Canada. He also holds a master's degree in biochemistry from the University of Western Ontario, Canada, and earned a master's degree in pharmacology and bachelor's degree in medicine from Second Military Medical University in China. Zeng is a Chartered Financial Analyst (CFA).
6 Biotechs with Staggering Potential: Grant Zeng (4/4/13) When it comes to picking biotech stocks, does a buyside perspective matter more than a sellside? Not according to Zacks Investment Research Analyst Grant Zeng, who has straddled the divide. What really matters is research of uncompromised quality. In this interview with The Life Sciences Report, Zeng offers a primer on what he looks for in a biotech investment, and names companies with the potential for big returns.
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng Moreá>
"CPRX has a few programs in indications that are less crowded and do not have many successful treatment options." (11/26/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Michael Hay Moreá>
"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay Moreá>
"We expect FDA approval in the near termŚlikely by the end of the yearŚfor OCLS' Microcyn Hydrogel device." (11/26/13) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Jocelyn August Moreá>